Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives.

O -GlcNAcylation is a dynamic post-translational modification mediated by O -linked β- N -acetylglucosamine transferase (OGT) and O -GlcNAc hydrolase (OGA), that adds or removes a single β- N -acetylglucosamine (GlcNAc) moiety to or from serine/threonine residues of nucleocytosolic and mitochondrial proteins, respectively. The perturbed homeostasis of O -GlcNAc cycling results in several pathological conditions. Human OGA is a promising therapeutic target in diseases where aberrantly low levels of O -GlcNAc are experienced, such as tauopathy in Alzheimer's disease. A new class of potent OGA inhibitors, 2-acetamido-2-deoxy- d -glucono-1,5-lactone (thio)semicarbazones, have been identified. Eight inhibitors were designed and synthesized in five steps starting from d -glucosamine and with 15–55% overall yields. A heterologous OGA expression protocol with strain selection and isolation has been optimized that resulted in stable, active and full length human OGA (hOGA) isomorph. Thermal denaturation kinetics of hOGA revealed environmental factors affecting hOGA stability. From kinetics experiments, the synthesized compounds proved to be efficient competitive inhibitors of hOGA with K i -s in the range of ∼30–250 nM and moderate selectivity with respect to lysosomal β-hexosaminidases. In silico studies consisting of Prime protein-ligand refinements, QM/MM optimizations and QM/MM-PBSA binding free energy calculations revealed the factors governing the observed potencies, and led to design of the most potent analogue 2-acetamido-2-deoxy- d -glucono-1,5-lactone 4-(2-naphthyl)-semicarbazone 6g (K i = 36 nM). The protocol employed has applications in future structure based inhibitor design targeting OGA. [Display omitted] • Synthesis of 2-acetamido-2-deoxy-D-glucono-1,5-lactone semicarbazones. • New, low nanomolar, competitive inhibitors of human OGA. • Expression and stability studies on human OGA. • In silico studies on the binding mode of the new inhibitors. [ABSTRACT FROM AUTHOR]